基于病例注册系统的甲状腺癌治疗及预后研究

注册号:

Registration number:

ChiCTR1800018760 

最近更新日期:

Date of Last Refreshed on:

2018-10-08 17:42:36 

注册时间:

Date of Registration:

2018-10-08 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

基于病例注册系统的甲状腺癌治疗及预后研究

Public title:

The Treatment and Prognosis Study of Thyroid Cancer Based on Cancer Registration System

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于病例注册系统的甲状腺癌治疗及预后研究

Scientific title:

The Treatment and Prognosis Study of Thyroid Cancer Based on Cancer Registration System

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

肖娟 

研究负责人:

贾红英 

Applicant:

Xiao Juan 

Study leader:

Jia Hongying 

申请注册联系人电话:

Applicant telephone:

+86 15106911635

研究负责人电话:

Study leader's
telephone:

+86 17660089053

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

xiaojuan8972@163.com

研究负责人电子邮件:

Study leader's E-mail:

jiahongying@sdu.edu.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

山东省济南市北园大街247号

研究负责人通讯地址:

山东省济南市北园大街247号

Applicant address:

247 Beiyuan Road, Jinan, Shandong, China

Study leader's address:

247 Beiyuan Road, Jinan, Shandong, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

山东大学第二医院

Applicant's institution:

The Second Hospital of Shandong University

研究负责人所在单位:

山东大学第二医院

Affiliation of the Leader:

The Second Hospital of Shandong University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

KYLL-2018(LW)013

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

山东大学第二医院伦理委员会

Name of the ethic committee:

The Institutional Review Board (IRB) of the Second Hospital of Shandong University

伦理委员会批准日期:

Date of approved by ethic committee:

2018-10-08 00:00:00

伦理委员会联系人:

鲜于俊杰

Contact Name of the ethic committee:

Xianyu Junjie

伦理委员会联系地址:

山东省济南市北园大街247号

Contact Address of the ethic committee:

247 Beiyuan Road, Jinan, Shandong, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

山东大学第二医院

Primary sponsor:

The Second Hospital of Shandong University

研究实施负责(组长)单位地址:

山东省济南市北园大街247号

Primary sponsor's address:

247 Beiyuan Road, Jinan, Shandong, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

山东省

市(区县):

Country:

China

Province:

Shandong

City:

单位(医院):

山东大学第二医院

具体地址:

山东省济南市北园大街247号

Institution
hospital:

The Second Hospital of Shandong University

Address:

247 Beiyuan Road, Jinan, Shandong

经费或物资来源:

山东大学博士生导师课题(横向)

Source(s) of funding:

The Research Project of Doctoral Supervisor of Shandong University

研究疾病:

甲状腺癌  

Target disease:

Thyroid Cancer

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

回顾性研究 

Study phase:

Retrospective study

研究设计:

队列研究 

Study design:

Cohort study 

研究目的:

1.构建甲状腺癌术前诊断影像学和实验室检查预测体系 2.构建不同手术方式、放射性碘治疗方式的比较效果研究 3.构建甲状腺癌转移复发的预测模型  

Objectives of Study:

1. To construct the preoperative diagnostic imaging and laboratory examination prediction system of thyroid cancer; 2. To compare the effects of different surgical methods and radioactive iodine treatments; 3. To construct prediction models of thyroid cancer recurrence and metastasis.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

精神障碍,无法正常进行语言交流;合并严重器官功能障碍;合并除妇科肿瘤外其他系统的恶性肿瘤患者

Exclusion criteria:

Mental disorders, inability to communicate normally;Combined with serious organ dysfunction;Patients with malignant tumors in addition to gynecological tumors

研究实施时间:

Study execute time:

From 2018-11-01 00:00:00 To 2020-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2018-12-01 00:00:00 To 2019-12-01 00:00:00

干预措施:

Interventions:

组别:

2

样本量:

500

Group:

Group 2

Sample size:

干预措施:

放射性碘治疗

干预措施代码:

Intervention:

radioactive iodine treatment

Intervention code:

组别:

1

样本量:

500

Group:

Group 1

Sample size:

干预措施:

手术

干预措施代码:

Intervention:

Surgery

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

山东省 

市(区县):

 

Country:

China

Province:

Shandong

City:

单位(医院):

山东大学第二医院 

单位级别:

三级甲等医院 

Institution
hospital:

The Second Hospital of Shandong University

Level of the institution:

Tertiary A Hospital

测量指标:

Outcomes:

指标中文名:

转移

指标类型:

主要指标

Outcome:

metastases

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 80 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

N/A

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

N/A

Blinding:

N/A

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

研究原始数据通过张贴的方式在山东大学第二医院公开栏进行,公开日期为本研究完成后的半年内

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

The original data was published in the public column of the Second Hospital of Shandong University. The publication date is within six months after the completion of the study.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据通过电子病历系统进行采集和管理

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Electronic Data Capture

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2018-10-08 17:42:37